fda tirzepatide announcement Grants a New Indication for Obesity Management FDA approves new version of

The FDA has now approved Zepbound specifically for OSA in adults with obesity , as long as they are unable or unwilling to use CPAP

Rather than acting broadly across the microbiome, it lives within the mucus layer itself, and early research suggests this is how it helps reinforce the gut barrier and support the body's everyday response to stressors

Liu lng ny s c iu chnh ph hp cng vi glutathione theo tng sn phm

Flaxseed supplementation in non-alcoholic fatty liver disease: a pilot randomized, open labeled, controlled study

Many patients experience reduced appetite and fluid intake when starting GLP-1 therapy, whilst the medicine's gastrointestinal effects including nausea and occasional vomiting can further affect hydration status